Exelixis announces collaborator Daiichi Sankyo's initiation of phase 3 trial for CS-3150
Exelixis announced its partner Daiichi Sankyo has initiated a phase 3 pivotal trial to evaluate CS-3150 (esaxerenone (r-INN)), an oral, non-steroidal, selective mineralocorticoid receptor antagonist, as treatment for essential hypertension in Japanese patients. September 26, 2016